Vertex Pharmaceuticals/VRTX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Vertex Pharmaceuticals

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Ticker

VRTX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Boston, United States

Employees

5,400

VRTX Metrics

BasicAdvanced
$122B
Market cap
30.58
P/E ratio
$15.41
EPS
0.39
Beta
-
Dividend rate
$122B
0.39
3.501
3.152
3.889
3.889
102.01%
12.81%
24.38%
30.58
11.93
6.56
7.32
34.93
10.61%
22.82%
16.66%
13.67%

What the Analysts think about VRTX

Analyst Ratings

Majority rating from 31 analysts.
Buy

VRTX Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
40.86% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$2.7B
6.87%
Net income
$1.1B
13.50%
Profit margin
40.86%
6.21%

VRTX Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 17.15%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$3.89
$4.08
$4.20
$4.76
-
Expected
$3.88
$3.97
$4.10
$4.06
$4.16
Surprise
0.21%
2.67%
2.37%
17.15%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Vertex Pharmaceuticals stock?

Vertex Pharmaceuticals (VRTX) has a market cap of $122B as of July 03, 2024.

What is the P/E ratio for Vertex Pharmaceuticals stock?

The price to earnings (P/E) ratio for Vertex Pharmaceuticals (VRTX) stock is 30.58 as of July 03, 2024.

Does Vertex Pharmaceuticals stock pay dividends?

No, Vertex Pharmaceuticals (VRTX) stock does not pay dividends to its shareholders as of July 03, 2024.

When is the next Vertex Pharmaceuticals dividend payment date?

Vertex Pharmaceuticals (VRTX) stock does not pay dividends to its shareholders.

What is the beta indicator for Vertex Pharmaceuticals?

Vertex Pharmaceuticals (VRTX) has a beta rating of 0.39. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy or sell Vertex Pharmaceuticals stock

Buy or sell Vertex Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing